Mesoblast to test cell therapy against COVID-19 lung disease

Published: 17 March 2020

Mesoblast Limited, an Australia-based regenerative medicine company, has announced its plan to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress syndrome caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. The COVID-19 pandemic is now a major global health threat. As of 16th March […]

Read now